Notice NOT-AT-20-007 from the NIH Guide for Grants and Contracts

Notice NOT-CA-20-027 from the NIH Guide for Grants and Contracts

Notice NOT-AA-20-003 from the NIH Guide for Grants and Contracts

Notice NOT-MH-20-032 from the NIH Guide for Grants and Contracts

Notice NOT-GM-20-014 from the NIH Guide for Grants and Contracts

Notice NOT-HL-20-749 from the NIH Guide for Grants and Contracts

Notice NOT-AA-20-002 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-20-077 from the NIH Guide for Grants and Contracts. With this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for investigator-initiated Program Project (P01) applications. The proposed Program may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each application submitted in response to this FOA must consist of at least three research projects and an Administrative Core. The projects must share a common central theme, focus, and/or overall objective.

Funding Opportunity RFA-AG-21-012 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites U24 Cooperative Agreement applications aiming to establish several mis-folded protein polymorphisms resource networks in the area of Alzheimer's disease and its related dementias (AD/ADRD). The central goal of these resource networks is to standardize and distribute seed, oligomers, and fibrils to other investigators in order to clarify and improve the reproducibility of experiments in AD/ADRD. For the past several years, many studies have developed assays and reagents to understand the biophysical properties of various tau and A structural variants such as oligomers, protofibrils, and fibrils. As a result, many imaging, chemical, and immunological tools have been developed to detect different types of A and tau polymorphs. Establishing standards, understanding the pathological roles of these protein polymorphs, and using newly developed analytic tools to address the direct correlation between patient-to-patient variations in A and tau polymorphs are the long-term goals of the resource networks supported by this FOA.

Notice NOT-HD-20-004 from the NIH Guide for Grants and Contracts

Notice NOT-AR-20-014 from the NIH Guide for Grants and Contracts

Notice NOT-AT-20-003 from the NIH Guide for Grants and Contracts

Notice NOT-DE-20-008 from the NIH Guide for Grants and Contracts

Notice NOT-HL-20-750 from the NIH Guide for Grants and Contracts

Notice NOT-HL-20-747 from the NIH Guide for Grants and Contracts

Notice NOT-MH-20-030 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-20-092 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to support the discovery and development of medications to prevent and treat opioid use disorders (OUD) and overdose. The UG3/UH3 Phase Innovation Awards Cooperative Agreement involves 2 phases. The UG3 is to support a project with specific milestones to be accomplished by the end of the 2-year period. The UH3 is to provide funding for 3 years to a project that successfully completed the milestones set in the UG3. UG3 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this FOA must address both UG3 and UH3 phases. Application may include preclinical or clinical research studies that will have high impact and quickly yield the necessary results to advance closer to FDA approval medications that are safe and effective to prevent and treat OUDs and overdose. The compounds to be evaluated can be small molecules or biologics. They can be tested in pre-clinical models and/or for the clinical manifestations of OUDs such as withdrawal, craving, relapse, or overdose. Applications may focus on the development of new chemical entities, new formulations of marketed medications available for other indications, or combinations of medications that hold promise for the treatment of OUDs and overdose. Through this FOA, NIDA seeks to fast-track the discovery and development of medications to prevent and treat OUDs or opioid overdose and to advance them in the FDA's drug development approval pipeline. This project is part of the NIH initiative to establish a public-private partnership to address the opioid crisis via more effective and safe ways to prevent and treat opioid use disorders and overdose. https://www.nih.gov/opioid-crisis

Funding Opportunity RFA-HL-20-031 from the NIH Guide for Grants and Contracts. This FOA invites applications for pre-clinical research to stimulate the development of novel, mechanism-based pharmacotherapies to selectively reverse breathing suppression produced by opioids. Two critical phases of pre-clinical investigation are supported. Phase I: the identification and rigorous validation of candidate targets; Phase II: development of therapeutic candidates, such as small molecules, biologics, and natural products that modulate validated targets identified in Phase I, using relevant animal models or human cells/tissue. Specific Phase I and II milestones, which will be formalized pre-award and serve as a schedule of performance expectations to maximize the output from each phase of the study. Milestone performance will be a major factor in determining which applications will be selected to transition from Phase I to Phase II. Phase II extends up to addressing preclinical functional outcomes, toxicology, and pharmacokinetics needed to support an Investigational New Drug (IND) application. Multi-disciplinary, multiple PI teams combining expertise in respiratory neurobiology, opioid pharmacology and pre-clinical drug development are strongly encouraged. This FOA is intended for pharmacotherapeutic development. Projects proposing device and model development or validation, the elucidation of biological mechanisms, population-based epidemiology, or human subjects research would not be responsive. Reversal of the respiratory depression, without inducing generalized opioid withdrawal, or interfering with analgesic effects addresses the ultimate goal of developing better medical strategies for management of deleterious consequences of synthetic illicit, as well as prescription opioids.

Notice NOT-MH-20-014 from the NIH Guide for Grants and Contracts

Notice NOT-AT-20-006 from the NIH Guide for Grants and Contracts